<DOC>
	<DOCNO>NCT01435395</DOCNO>
	<brief_summary>This single-center ( Emory University ) , open-label , single arm , phase I study assess safety toxicity bortezomib combination bevacizumab escalate dos temozolomide patient recurrent glioblastoma multiforme . Patients require anti-epileptic medication least 10 day EIAEDs . Only non-EIAEDs accept .</brief_summary>
	<brief_title>Trial Temozolomide , Bevacizumab Plus Bortezomib Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Age 18 year . 2 . Patients must histologically confirm diagnosis recurrent/progressive WHO grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) . 3 . Patients must measurable progressive recurrent disease MRI within 2 week start treatment . 4 . No prior bortezomib allow . 5 . An interval least 6 week prior surgical resection , 4 week end prior radiotherapy . 6 . Patients must least 10 day enzyme induce antiepileptic drug ( EIAEDs ) cytochrome P450 ( CYP450 ) phenytoin , carbamazepine , phenobarbital . 7 . Karnofsky performance status score 60 . 8 . Patients must recover toxicity prior therapy . 9 . Hematocrit &gt; 29 % , absolute neutrophil count ( ANC ) &gt; 1,500 cells/microliter , platelet &gt; 125,000 cells/microliter 14 day prior treatment initiation . 10 . Serum creatinine &lt; 1.5 mg/dl , serum glutamicoxaloacetic transaminase ( SGOT ) bilirubin &lt; 1.5 time upper limit normal . 11 . Prothrombin time/international normalize ratio ( PT INR ) &lt; 1.4 . 12 . An interval least 3 month completion recent radiation therapy . At least 4 week nonnitrosourea chemotherapy regimen least 6 week nitrosourea contain regimen . 13 . For patient corticosteroid , must stable dose 1 week prior entry clinically recommend . 14 . May three biological therapy . 15 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 16 . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . 17 . Male subject agree use acceptable method contraception duration study . 1 . Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid . 2 . Greater three prior recurrence . 3 . Enzymeinducing antiepileptic drug ( EIAEDs ) CYP450 phenytoin , carbamazepine , phenobarbital . 4 . Patients receive concurrent investigational drug . 5 . Evidence central nervous system ( CNS ) hemorrhage baseline MRI CT scan ( except grade 1 hemorrhage stable least 3 month ) . 6 . History stroke within six month . 7 . Requires therapeutic anticoagulation . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic psychiatric illness/social situation would limit compliance study requirement , disorder associate significant immunocompromised state . 9 . Patient calculate measured creatinine clearance &lt; 20 mL/minute within 14 day prior treatment initiation . 10 . Patient great equal Grade 2 peripheral neuropathy within 14 day enrollment . 11 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( Appendix ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . 12 . Patient hypersensitivity bortezomib , boron , mannitol . 13 . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . 14 . Patient receive investigational drug within 14 day treatment initiation 15 . Serious medical psychiatric illness likely interfere participation clinical study . 16 . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Patients prior malignancy must disease free least 5 year . 17 . Serious , nonhealing wound , active ulcer , untreated bone fracture . Bone fracture must heal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>